Imagine regaining viral suppression, even if other HIV-1 treatments have failed you. TROGARZO® (ibalizumab-uiyk) is a breakthrough in HIV-1 treatment, the first and only long-acting antiviral, designed specifically for those with second-line regimen failure.1,2
*Undetectable viral load is defined as fewer than 50 copies of HIV per mL of blood.
This is the experience of one patient and may not be representative of all TROGARZO® patients.
If you have experienced treatment failures, it may feel like getting your viral load back to undetectable levels is out of reach.
Imagine regaining viral suppression,
even if other treatments have failed you.
To combat HIV-1 when treatment fails, a regimen should be modified as soon as possible to avoid further resistance. The most effective HIV-1 treatment regimen is one that combines 3 active antiretroviral medicines. An active antiretroviral medicine could be a new type you didn’t try before.
In a clinical study, TROGARZO® was proven to have a significant and long-lasting impact on the amount HIV-1 in the body, reducing or “lightening” viral load.
83% of patients
were able to
reduce their HIV-1 viral load
after receiving a single dose of TROGARZO®.
Also, studies showed that patients who reached undetectable were able to remain undetectable over time. TROGARZO® does not interact with other drugs, so you can take it with other medications you may be taking. Be sure to discuss other medications you may be taking with your healthcare provider before taking TROGARZO®.
TROGARZO® is a medicine that’s used in combination with other antiretroviral medicines to treat HIV-1 infection in adults who:
Have been on different HIV-1 treatment regimens in the past, and
Have HIV-1 that is resistant to antiretroviral medicines, and
Are currently on an HIV-1 treatment regimen that is failing
THE FIRST AND ONLY LONG-ACTING ANTIVIRAL AGAINST HIV-1
TROGARZO® works differently. Unlike antiretroviral medicines that aim to prevent HIV-1 from multiplying inside the immune system’s T-cells, it is a biologic - an antibody bioengineered specifically to protect your T-cells from the virus. TROGARZO® binds to the T-cell’s surface to block HIV-1 from entering.
This can help protect the T-cell and reduce or “lighten” your viral load.
TROGARZO® is not a daily pill. It’s an intravenous (IV) infusion given over 15 to 30 minutes every 2 weeks. Infusion appointments can be a great time to ask any questions you may have about your treatment, or simply keep in touch with your care provider.
every 2 weeks
Appointments arranged by your personal Patient Care Coordinator
Given by a healthcare provider at home, an infusion center or healthcare provider’s office
Asking the right questions is an important part of getting the most from your HIV-1 treatment.
Here are some questions to help get the conversation started:
What is my HIV-1 viral load?
What is resistance?
Do I need resistance testing?
Which classes of HIV-1 treatments am I resistant to?
What fully active agents are available to me?
Am I currently on two or three fully active agents?
How many HIV-1 treatment options do I have left?
Could I benefit from adding TROGARZO® to my treatment plan?
We’re here to help make your journey as smooth as possible and answer any questions you may have. Once TROGARZO® becomes a part of your regimen, you’ll receive a welcome call from your dedicated Patient care coordinator. We can also assist with your private or government insurance coverage, including AIDS Drug Assistance Program (ADAP) and will also assist in applying any eligible co‑pay assistance. From appointment reminders to insurance coverage assistance, and anything in between, our knowledgeable team is here to help.
I would like more information about:
Reference: 1. TROGARZO® Prescribing Information. Theratechnologies Inc. March 6, 2018. TROGARZO® Prescribing Information. Theratechnologies Inc. May 2018. 2. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV, October 2018.
Download the TROGARZO® Patient Information, which includes complete product information.Download
IMPORTANT SAFETY INFORMATION
TROGARZO® can cause serious side effects, including changes in your immune system (Immune Reconstitution Inflammatory Syndrome) which can happen when you start taking HIV-1 medicines. Your immune system might get stronger and begin to fight infections that have been hidden in your body for a long time. This may result in an inflammatory response which may require further evaluation and treatment. Tell your healthcare provider right away if you start having new symptoms after receiving TROGARZO®.
The most common side effects of TROGARZO® include diarrhea, dizziness, nausea, rash. These are not all the possible side effects of TROGARZO®.
Before you receive TROGARZO®, tell your healthcare provider:
About all your medical conditions.
About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
If you are pregnant or plan to become pregnant. It is not known if TROGARZO® may harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with TROGARZO®.
If you are breastfeeding or plan to breastfeed. Do not breastfeed if you are receiving TROGARZO® as it is not known if TROGARZO® passes into breast milk. You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby.
WHAT IS TROGARZO®?
TROGARZO® (ibalizumab-uiyk) is a prescription medicine that is used with other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults who:
have received anti-HIV-1 regimens in the past, and
have HIV-1 virus that is resistant to antiretroviral medicines, and
who are failing their current antiretroviral therapy.
It is not known if TROGARZO® is safe and effective in children.